Skip to content

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01662791
Enrollment
49
Registered
2012-08-10
Start date
2012-09-30
Completion date
2015-03-31
Last updated
2016-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Parkinson's Disease, Small Bowel Bacterial Overgrowth, Weight Loss, Gastrointestinal, Rifaximin

Brief summary

The potential role of small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with Parkinson's Disease (PD) has not previously been examined. Our hypothesis was that SBBO is an important contributor to the development of weight loss in individuals with PD. The investigators proposed to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a poorly absorbed antibiotic. The investigators performed a prospective, observational case-control study (Part 1) with an open-label therapeutic component (Part 2). Cases were defined as those PD patients who experienced significant weight loss while Controls were defined as those PD patients who did not experience significant weight loss.

Detailed description

Part 1: Consecutive patients seen in the Parkinson's disease clinic at Mayo Clinic in Arizona were approached to participate. After the determination of their eligibility and appropriate signed informed consent, all PD patients (i.e., both Case and Control groups) underwent the following: 1. Assessment of demographic features, weight history and PD history 2. PD and other medications 3. Determination of PD severity using the Unified Parkinson's Disease rating scale 4. Gastrointestinal Symptom Severity Index (GISSI) and modified GISSI. 5. Determination of usual calorie and nutrient intake (Brief Block Food Frequency Questionnaire) 6. Paffenbarger physical activity questionnaire 7. Quality of life (SF12 and PD-specific) 8. Hospital Anxiety and Depression Scale 9. Glucose hydrogen breath test (SBBO test) 10. Qualitative assessments of smell and taste All questionnaires were completed during the 2 hour breath test. Part 2: All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day for 14 days. Treatment did not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects could have received antibiotic treatment. The patient was contacted by phone 1 month after treatment at which time the presence of GI symptoms was determined and inquiry made about any adverse effects related to rifaximin use. GI symptoms, quality of life, weight measurement, and breath testing were repeated at a 3 month study visit.

Interventions

DRUGRifaximin

All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Parkinson's Disease

Exclusion criteria

1. Wheelchair-bound, akinetic individuals 2. Tube-fed individuals 3. Presence of dementia 4. Unwilling or unable to complete the tests 5. Allergic or intolerant to rifaximin 6. Presence of chronic upper or lower gastrointestinal disorders that have symptoms that may be confused with SBBO (e.g., irritable bowel syndrome, inflammatory bowel disease, celiac disease, functional dyspepsia, gastroparesis, and chronic pancreatitis) 7. Presence of prior surgery on the gastrointestinal tract except cholecystectomy, appendectomy or herniorrhaphy 8. Presence of severe concomitant acute or chronic medical condition that may interfere with the completion or interpretation of the test results 9. Women of childbearing potential. Given the age of patients with Parkinson's disease, we do not anticipate this being a large population. 10. Use of antibiotics within 1 month of breath testing

Design outcomes

Primary

MeasureTime frameDescription
Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO)Baseline to 2 hoursSBBO is measured by the Hydrogen Breath Test, which measures the hydrogen and methane gas produced by bacteria in the small bowel that has diffused into the blood, then lungs for expiration. After an overnight fast, subjects ingested a solution consisting of 50 grams of glucose mixed in 150 mL of water. Immediately before ingestion of glucose and at 20-minute intervals for 2 hours following ingestion, laboratory staff collected end-expiratory breath samples and analyzed them for hydrogen and methane using a Quintron sample correction (SC) breath microlyzer. A diagnosis of SBBO was defined by an increase in expiration of 12 parts per million (ppm) or more of hydrogen and/or methane.

Secondary

MeasureTime frameDescription
PD-specific Quality of Life Questionnaire (PDQ-39)baselineThe PDQ-39 is designed to address aspects of functioning and well-being for those affected by Parkinson's disease. This questionnaire is based on a multi-dimensional model of health. Eight subscale scores may be derived from the items: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), bodily discomfort (3 items). Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert Scale): Never/occasionally/sometimes/often/always or cannot do at all. Each dimension is calculated as a scale from 0 to 100, with 0= no problem at all; 100= maximum level of problem. Sub-scale score are averaged to calculate the summary index.
PD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupBaseline and 3 monthsThe PDQ-39 is designed to address aspects of functioning and well-being for those affected by Parkinson's disease. This questionnaire is based on a multi-dimensional model of health. Eight subscale scores may be derived from the items: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), bodily discomfort (3 items). Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert Scale): Never/occasionally/sometimes/often/always or cannot do at all. Each dimension is calculated as a scale from 0 to 100, with 0= no problem at all; 100= maximum level of problem. Sub-scale score are averaged to calculate the summary index.
Gastrointestinal Symptom Severity Index (GISSI)BaselineThe GISSI is a validated, self-administered, multi-dimensional instrument designed to measure the frequency, severity and bothersomeness of individual GI symptoms and to provide subscale scores for interrelated symptom clusters. Factor analyses yielded 5 distinct symptom clusters that were labeled as Constipation/Difficult defecation; Abdominal Pain/Discomfort; Dyspepsia; Diarrhea/Fecal incontinence; Gastroesophageal reflux disease (GERD)/Chest symptoms; and Nausea/Vomiting. Scores could range from 0 to 100, with a higher score indicating greater severity of symptoms.
Hospital Anxiety and Depression Scale (HADS)BaselineThe HADS is a self-administered 14-item questionnaire (seven for anxiety and seven for depression) Items are rated on a 4-point scale from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. The cut-offs used for identifying significant psychiatric distress was \>/= 8. This assessment was only measured at baseline
Weight Change in Case Group After Treatmentbaseline, 3 monthsWeight change after treatment
Paffenbarger Physical Activity Questionnaire (PPAQ)BaselineThe PPAQ is a validated, self-administered questionnaire that asks for a recall of physical activity of physical activity over the previous 1-week. From the answers to the questions, a physical activity index (PAI) can be computed, providing an estimate of energy expenditure in kcal/week. The PAI can be estimated using a list of the physical activities a person performs within a time period and the amount of time spent on each activity, e.g. walking to work, light housework, swimming, carrying bricks at work, or whatever applies to an individual person. There is a value called the physical activity ratio for each activity. The list of activities is used to find the relevant values of physical activity ratios, then an overall physical activity level value for the time period is calculated, using time-weighted averages of the physical activity ratios. This assessment was only measured at baseline.
Gastrointestinal Symptom Severity Index (GISSI) Over Time in Case Groupbaseline, 3 monthsThe GISSI is a validated, self-administered, multi-dimensional instrument designed to measure the frequency, severity and bothersomeness of individual GI symptoms and to provide subscale scores for interrelated symptom clusters. Factor analyses yielded 5 distinct symptom clusters that were labeled as Constipation/Difficult defecation; Abdominal Pain/Discomfort; Dyspepsia; Diarrhea/Fecal incontinence; Gastroesophageal reflux disease (GERD)/Chest symptoms; and Nausea/Vomiting. Scores could range from 0 to 100, with a higher score indicating greater severity of symptoms.

Other

MeasureTime frameDescription
Calories Consumed From Brief Block Food Frequency Questionnaire (FFQ)BaselineThe FFQ is a validated, self-administered semi-quantitative questionnaire used to assess differences in macronutrient, and energy intake. It was designed to provide estimates of usual and customary dietary intake. This questionnaire contains a food list of about 70 food items. A Food Frequency Questionnaire (FFQ) is a limited checklist of foods and beverages with a frequency response section for subjects to report how often each item was consumed over a specified period of time. Semi-quantitative FFQs collect portion size information as standardized portions or as a choice of portion sizes. Calculations for nutrient intake or calories can be estimated via computerized software programs that multiply the reported frequency of each food by the amount of nutrient or calories in a serving of that food.

Countries

United States

Participant flow

Recruitment details

Subjects were recruited at the Mayo Clinic in Scottsdale, Arizona.

Participants by arm

ArmCount
Case Group
All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Subjects in the case group were in the study for 3 months. Rifaximin: All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment did not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
8
Control Group
This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
41
Total49

Baseline characteristics

CharacteristicCase GroupControl GroupTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
8 Participants30 Participants38 Participants
Age, Categorical
Between 18 and 65 years
0 Participants11 Participants11 Participants
Region of Enrollment
United States
8 participants41 participants49 participants
Sex: Female, Male
Female
2 Participants17 Participants19 Participants
Sex: Female, Male
Male
6 Participants24 Participants30 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
2 / 81 / 41
serious
Total, serious adverse events
0 / 80 / 41

Outcome results

Primary

Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO)

SBBO is measured by the Hydrogen Breath Test, which measures the hydrogen and methane gas produced by bacteria in the small bowel that has diffused into the blood, then lungs for expiration. After an overnight fast, subjects ingested a solution consisting of 50 grams of glucose mixed in 150 mL of water. Immediately before ingestion of glucose and at 20-minute intervals for 2 hours following ingestion, laboratory staff collected end-expiratory breath samples and analyzed them for hydrogen and methane using a Quintron sample correction (SC) breath microlyzer. A diagnosis of SBBO was defined by an increase in expiration of 12 parts per million (ppm) or more of hydrogen and/or methane.

Time frame: Baseline to 2 hours

ArmMeasureGroupValue (NUMBER)
Case GroupNumber of Subjects With Small Bowel Bacterial Overgrowth (SBBO)12 ppm increase2 participants
Case GroupNumber of Subjects With Small Bowel Bacterial Overgrowth (SBBO)20 ppm increase2 participants
Control GroupNumber of Subjects With Small Bowel Bacterial Overgrowth (SBBO)12 ppm increase12 participants
Control GroupNumber of Subjects With Small Bowel Bacterial Overgrowth (SBBO)20 ppm increase9 participants
Comparison: Comparison between the groups for \>12 ppm.p-value: 1Chi-squared
Secondary

Gastrointestinal Symptom Severity Index (GISSI)

The GISSI is a validated, self-administered, multi-dimensional instrument designed to measure the frequency, severity and bothersomeness of individual GI symptoms and to provide subscale scores for interrelated symptom clusters. Factor analyses yielded 5 distinct symptom clusters that were labeled as Constipation/Difficult defecation; Abdominal Pain/Discomfort; Dyspepsia; Diarrhea/Fecal incontinence; Gastroesophageal reflux disease (GERD)/Chest symptoms; and Nausea/Vomiting. Scores could range from 0 to 100, with a higher score indicating greater severity of symptoms.

Time frame: Baseline

ArmMeasureGroupValue (MEAN)Dispersion
Case GroupGastrointestinal Symptom Severity Index (GISSI)Constipation22.6 units on a scaleStandard Deviation 20.8
Case GroupGastrointestinal Symptom Severity Index (GISSI)Dyspepsia7.2 units on a scaleStandard Deviation 11.5
Case GroupGastrointestinal Symptom Severity Index (GISSI)Abdominal Pain/Discomfort8.1 units on a scaleStandard Deviation 16.5
Case GroupGastrointestinal Symptom Severity Index (GISSI)Diarrhea3.4 units on a scaleStandard Deviation 4.9
Case GroupGastrointestinal Symptom Severity Index (GISSI)GERD5.6 units on a scaleStandard Deviation 10.6
Case GroupGastrointestinal Symptom Severity Index (GISSI)Nausea/Vomiting1.6 units on a scaleStandard Deviation 3.1
Control GroupGastrointestinal Symptom Severity Index (GISSI)GERD3.4 units on a scaleStandard Deviation 5.2
Control GroupGastrointestinal Symptom Severity Index (GISSI)Constipation14.5 units on a scaleStandard Deviation 15.8
Control GroupGastrointestinal Symptom Severity Index (GISSI)Diarrhea2.7 units on a scaleStandard Deviation 6.2
Control GroupGastrointestinal Symptom Severity Index (GISSI)Dyspepsia4.5 units on a scaleStandard Deviation 6.6
Control GroupGastrointestinal Symptom Severity Index (GISSI)Nausea/Vomiting0.63 units on a scaleStandard Deviation 2.4
Control GroupGastrointestinal Symptom Severity Index (GISSI)Abdominal Pain/Discomfort6.6 units on a scaleStandard Deviation 10.2
Comparison: Comparison between groups for constipation sub-scale.p-value: 0.303Chi-squared
Comparison: Comparison between groups for dyspepsia sub-scale.p-value: 0.518Chi-squared
Comparison: Comparison between groups for abdominal discomfort sub-scale.p-value: 0.8Chi-squared
Comparison: Comparison between groups for diarrhea sub-scale.p-value: 0.736Chi-squared
Comparison: Comparison between groups for GERD sub-scale.p-value: 0.57Chi-squared
Comparison: Comparison between groups for nausea and vomiting sub-scale.p-value: 0.394Chi-squared
Secondary

Gastrointestinal Symptom Severity Index (GISSI) Over Time in Case Group

The GISSI is a validated, self-administered, multi-dimensional instrument designed to measure the frequency, severity and bothersomeness of individual GI symptoms and to provide subscale scores for interrelated symptom clusters. Factor analyses yielded 5 distinct symptom clusters that were labeled as Constipation/Difficult defecation; Abdominal Pain/Discomfort; Dyspepsia; Diarrhea/Fecal incontinence; Gastroesophageal reflux disease (GERD)/Chest symptoms; and Nausea/Vomiting. Scores could range from 0 to 100, with a higher score indicating greater severity of symptoms.

Time frame: baseline, 3 months

ArmMeasureGroupValue (MEAN)Dispersion
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupConstipation baseline32.3 units on a scaleStandard Deviation 29.8
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupConstipation 3 months10.0 units on a scaleStandard Deviation 10.6
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupDyspepsia baseline12.9 units on a scaleStandard Deviation 20.6
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupDyspepsia 3 months8.2 units on a scaleStandard Deviation 15.5
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupAbdominal Pain/Discomfort baseline14.5 units on a scaleStandard Deviation 29.4
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupAbdominal Pain/Discomfort 3 months4.0 units on a scaleStandard Deviation 7.5
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupDiarrhea baseline6.0 units on a scaleStandard Deviation 8.7
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupDiarrhea 3 months12.7 units on a scaleStandard Deviation 19.8
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupGERD baseline10.0 units on a scaleStandard Deviation 18.9
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupGERD 3 months8.5 units on a scaleStandard Deviation 12.9
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupNausea/Vomiting baseline5.8 units on a scaleStandard Deviation 11.1
Case GroupGastrointestinal Symptom Severity Index (GISSI) Over Time in Case GroupNausea/Vomiting 3 months2.2 units on a scaleStandard Deviation 6.3
Comparison: Comparison in case group between baseline and 3 months for constipation sub-scale.p-value: 0.056McNemar
Comparison: Comparison in case group between baseline and 3 months for dyspepsia sub-scale.p-value: 0.38McNemar
Comparison: Comparison in case group between baseline and 3 months for abdominal discomfort sub-scale.p-value: 0.244McNemar
Comparison: Comparison in case group between baseline and 3 months for diarrhea sub-scale.p-value: 0.279McNemar
Comparison: Comparison in case group between baseline and 3 months for GERD sub-scale.p-value: 0.554McNemar
Comparison: Comparison in case group between baseline and 3 months for nausea and vomiting sub-scale.p-value: 0.351McNemar
Secondary

Hospital Anxiety and Depression Scale (HADS)

The HADS is a self-administered 14-item questionnaire (seven for anxiety and seven for depression) Items are rated on a 4-point scale from 0-3 and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. The cut-offs used for identifying significant psychiatric distress was \>/= 8. This assessment was only measured at baseline

Time frame: Baseline

ArmMeasureGroupValue (MEAN)Dispersion
Case GroupHospital Anxiety and Depression Scale (HADS)Depression3.5 units on a scaleStandard Deviation 3.7
Case GroupHospital Anxiety and Depression Scale (HADS)Anxiety3.8 units on a scaleStandard Deviation 3.8
Control GroupHospital Anxiety and Depression Scale (HADS)Depression3.3 units on a scaleStandard Deviation 2.1
Control GroupHospital Anxiety and Depression Scale (HADS)Anxiety4.0 units on a scaleStandard Deviation 2.6
Comparison: Comparison between the two groups at baseline for depressionp-value: 0.872t-test, 1 sided
Comparison: Comparison between the two groups at baseline for anxiety.p-value: 0.835t-test, 1 sided
Secondary

Paffenbarger Physical Activity Questionnaire (PPAQ)

The PPAQ is a validated, self-administered questionnaire that asks for a recall of physical activity of physical activity over the previous 1-week. From the answers to the questions, a physical activity index (PAI) can be computed, providing an estimate of energy expenditure in kcal/week. The PAI can be estimated using a list of the physical activities a person performs within a time period and the amount of time spent on each activity, e.g. walking to work, light housework, swimming, carrying bricks at work, or whatever applies to an individual person. There is a value called the physical activity ratio for each activity. The list of activities is used to find the relevant values of physical activity ratios, then an overall physical activity level value for the time period is calculated, using time-weighted averages of the physical activity ratios. This assessment was only measured at baseline.

Time frame: Baseline

ArmMeasureValue (MEAN)Dispersion
Case GroupPaffenbarger Physical Activity Questionnaire (PPAQ)848.8 kcal/weekStandard Deviation 566.5
Control GroupPaffenbarger Physical Activity Questionnaire (PPAQ)2253 kcal/weekStandard Deviation 2027
Secondary

PD-specific Quality of Life Questionnaire (PDQ-39)

The PDQ-39 is designed to address aspects of functioning and well-being for those affected by Parkinson's disease. This questionnaire is based on a multi-dimensional model of health. Eight subscale scores may be derived from the items: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), bodily discomfort (3 items). Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert Scale): Never/occasionally/sometimes/often/always or cannot do at all. Each dimension is calculated as a scale from 0 to 100, with 0= no problem at all; 100= maximum level of problem. Sub-scale score are averaged to calculate the summary index.

Time frame: baseline

ArmMeasureGroupValue (MEAN)Dispersion
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Activities of Daily Living25.0 units on a scaleStandard Deviation 14.1
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Cognition32.0 units on a scaleStandard Deviation 31.4
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Stigma13.3 units on a scaleStandard Deviation 25.5
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Communication25.0 units on a scaleStandard Deviation 27.1
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Emotional Well-Being17.2 units on a scaleStandard Deviation 23.5
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Bodily Discomfort24.0 units on a scaleStandard Deviation 22.9
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Social Support3.1 units on a scaleStandard Deviation 6.2
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Summary Index20.3 units on a scaleStandard Deviation 19.3
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39)Mobility23.1 units on a scaleStandard Deviation 20.1
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Summary Index13.5 units on a scaleStandard Deviation 9
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Mobility14.0 units on a scaleStandard Deviation 17.6
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Activities of Daily Living18.1 units on a scaleStandard Deviation 13.3
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Emotional Well-Being13.2 units on a scaleStandard Deviation 11.5
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Stigma6.2 units on a scaleStandard Deviation 9.9
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Social Support1.4 units on a scaleStandard Deviation 4.9
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Cognition17.5 units on a scaleStandard Deviation 12.8
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Communication10.8 units on a scaleStandard Deviation 13.3
Control GroupPD-specific Quality of Life Questionnaire (PDQ-39)Bodily Discomfort27.0 units on a scaleStandard Deviation 22.7
Comparison: Comparison between groups for mobility sub-scale.p-value: 0.235Chi-squared
Comparison: Comparison between groups for activities of daily living sub-scale.p-value: 0.206Chi-squared
Comparison: Comparison between groups for emotional well-being sub-scale.p-value: 0.641Chi-squared
Comparison: Comparison between groups for stigma sub-scale.p-value: 0.446Chi-squared
Comparison: Comparison between groups for social support sub-scale.p-value: 0.466Chi-squared
Comparison: Comparison between groups for cognition sub-scale.p-value: 0.205Chi-squared
Comparison: Comparison between groups for communication sub-scale.p-value: 0.153Chi-squared
Comparison: Comparison between groups for bodily discomfort sub-scale.p-value: 0.73Chi-squared
Comparison: Comparison between groups for summary index sub-scale.p-value: 0.334Chi-squared
Secondary

PD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case Group

The PDQ-39 is designed to address aspects of functioning and well-being for those affected by Parkinson's disease. This questionnaire is based on a multi-dimensional model of health. Eight subscale scores may be derived from the items: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognitions (4 items), communication (3 items), bodily discomfort (3 items). Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (Likert Scale): Never/occasionally/sometimes/often/always or cannot do at all. Each dimension is calculated as a scale from 0 to 100, with 0= no problem at all; 100= maximum level of problem. Sub-scale score are averaged to calculate the summary index.

Time frame: Baseline and 3 months

ArmMeasureGroupValue (MEAN)Dispersion
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupMobility baseline23.1 units on a scaleStandard Deviation 20.1
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupMobility 3 months27.8 units on a scaleStandard Deviation 25.5
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupActivities of Daily Living baseline25.0 units on a scaleStandard Deviation 14.1
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupActivities of Daily Living 3 months17.7 units on a scaleStandard Deviation 17.8
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupEmotional Well-Being baseline17.2 units on a scaleStandard Deviation 23.5
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupEmotional Well-Being 3 months11.0 units on a scaleStandard Deviation 22.9
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupStigma baseline13.3 units on a scaleStandard Deviation 25.5
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupStigma 3 months5.5 units on a scaleStandard Deviation 11.3
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupSocial Support baseline3.1 units on a scaleStandard Deviation 6.2
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupSocial Support 3 months3.1 units on a scaleStandard Deviation 6.2
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupCognition baseline32.0 units on a scaleStandard Deviation 31.4
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupCognition 3 months21.9 units on a scaleStandard Deviation 16.7
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupCommunication baseline25.0 units on a scaleStandard Deviation 27.1
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupCommunication 3 months15.6 units on a scaleStandard Deviation 10.4
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupBodily Discomfort baseline24.0 units on a scaleStandard Deviation 22.9
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupBodily Discomfort 3 months30.2 units on a scaleStandard Deviation 31.2
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupSummary Index baseline20.3 units on a scaleStandard Deviation 19.3
Case GroupPD-specific Quality of Life Questionnaire (PDQ-39) Over Time in Case GroupSummary Index 3 months16.6 units on a scaleStandard Deviation 13.3
Comparison: Comparison in case group between baseline and 3 months for mobility sub-scale.p-value: 0.167McNemar
Comparison: Comparison in case group between baseline and 3 months for activities of daily living sub-scale.p-value: 0.159McNemar
Comparison: Comparison in case group between baseline and 3 months for emotional well-being sub-scale.p-value: 0.041McNemar
Comparison: Comparison in case group between baseline and 3 months for stigma sub-scale.p-value: 0.19McNemar
Comparison: Comparison in case group between baseline and 3 months for social support sub-scale.p-value: 1McNemar
Comparison: Comparison in case group between baseline and 3 months for cognition sub-scale.p-value: 0.16McNemar
Comparison: Comparison in case group between baseline and 3 months for communication sub-scale.p-value: 0.276McNemar
Comparison: Comparison in case group between baseline and 3 months for bodily discomfort sub-scale.p-value: 0.351McNemar
Comparison: Comparison in case group between baseline and 3 months for summary index sub-scale.p-value: 0.186McNemar
Secondary

Weight Change in Case Group After Treatment

Weight change after treatment

Time frame: baseline, 3 months

ArmMeasureGroupValue (NUMBER)
Case GroupWeight Change in Case Group After TreatmentSubjects who lost weight from baseline3 participants
Case GroupWeight Change in Case Group After TreatmentSubjects who gained weight from baseline5 participants
Other Pre-specified

Calories Consumed From Brief Block Food Frequency Questionnaire (FFQ)

The FFQ is a validated, self-administered semi-quantitative questionnaire used to assess differences in macronutrient, and energy intake. It was designed to provide estimates of usual and customary dietary intake. This questionnaire contains a food list of about 70 food items. A Food Frequency Questionnaire (FFQ) is a limited checklist of foods and beverages with a frequency response section for subjects to report how often each item was consumed over a specified period of time. Semi-quantitative FFQs collect portion size information as standardized portions or as a choice of portion sizes. Calculations for nutrient intake or calories can be estimated via computerized software programs that multiply the reported frequency of each food by the amount of nutrient or calories in a serving of that food.

Time frame: Baseline

ArmMeasureGroupValue (MEAN)Dispersion
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Saturated Fat12.7 CaloriesStandard Deviation 3.8
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Carbohydrate45.1 CaloriesStandard Deviation 7.6
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Fat36.3 CaloriesStandard Deviation 9.6
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Alcohol14.8 CaloriesStandard Deviation 9.3
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Protein13.4 CaloriesStandard Deviation 3.1
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Sweets10.9 CaloriesStandard Deviation 15.3
Case GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Total calories consumed1503.7 CaloriesStandard Deviation 395.6
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Sweets6.5 CaloriesStandard Deviation 7.1
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Total calories consumed1588.0 CaloriesStandard Deviation 538.7
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Fat38.0 CaloriesStandard Deviation 6.5
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Saturated Fat13.0 CaloriesStandard Deviation 3
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Protein15.7 CaloriesStandard Deviation 3.4
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Carbohydrate43.7 CaloriesStandard Deviation 6.9
Control GroupCalories Consumed From Brief Block Food Frequency Questionnaire (FFQ)Alcohol12.5 CaloriesStandard Deviation 8.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026